title: [Standard treatment for myositis and muscular dystrophies].
abstract: We summarize the current therapeutic strategies and options in inflammatory myositis and the muscular dystrophies. In myositis, the therapeutic options include basic therapy with glucocorticosteroids and other standard immunosuppressive agents, and in individual cases escalating treatment with chemotherapy or monoclonal antibodies. The exact therapeutic sequence should be performed depending on the type of myositis and the response to immunosuppression.At present, there are still no effective causative interventions to significantly alter the progression of the muscular dystrophies. However, first gene therapy clinical studies have been started in some forms of muscular dystrophy which may open a new field of therapeutic options. Most patients with myositis or muscular dystrophy need symptom-oriented therapies which include physical therapy, adequate cardiorespiratory treatment and orthopedic interventions. In the future novel immunosuppressive options may be available in patients with myositis and possibly causative strategies in the muscular dystrophies.
authors: Abteilung Neurologie, Universitätsmedizin Göttingen, Göttingen.
authors: J
authors: J
authors: Schmidt
authors: M
authors: M
authors: Vorgerd
references: Brain. 2008 May;131(Pt 5):1228-40
references: 18420712
references: N Engl J Med. 2007 Dec 27;357(26):2677-86
references: 18160687
references: Ann Neurol. 2010 Jun;67(6):771-80
references: 20517938
references: Neurology. 2007 Jan 2;68(1):59-61
references: 17200494
references: Lancet Neurol. 2010 Nov;9(11):1053-9
references: 20801085
references: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004760
references: 17253521
references: N Engl J Med. 1992 May 21;326(21):1380-4
references: 1472183
references: Ann Neurol. 2010 Nov;68(5):629-38
references: 21031578
references: Ann Neurol. 2005 May;57(5):664-78
references: 15852401
references: Ann Neurol. 2007 May;61(5):476-83
references: 17469125
references: Neurology. 2004 Aug 24;63(4):718-20
references: 15326251
references: Muscle Nerve. 2008 Apr;37(4):473-6
references: 18236463
references: Neuromuscul Disord. 2010 Feb;20(2):122-4
references: 20071171
references: Ann Neurol. 2008 Jul;64(1):15-24
references: 18318434
references: Arthritis Rheum. 2005 Feb;52(2):601-7
references: 15692974
references: Eur J Paediatr Neurol. 2007 Nov;11(6):353-7
references: 17446099
references: Expert Opin Med Diagn. 2010 May;4(3):241-50
references: 23488533
references: Neurology. 2003 Jul 22;61(2):260-2
references: 12874415
references: J Rheumatol. 2007 Sep;34(9):1864-8
references: 17722224
references: Lancet Neurol. 2010 Jan;9(1):77-93
references: 19945913
references: Arthritis Rheum. 2007 May 15;57(4):694-702
references: 17471547
references: Lancet. 2003 Sep 20;362(9388):971-82
references: 14511932
references: Neurology. 2006 Jan 24;66(2 Suppl 1):S30-2
references: 16432142
references: J Neurol Neurosurg Psychiatry. 2009 Oct;80(10):1060-8
references: 19762898
references: Ann Neurol. 2006 Nov;60(5):603-10
references: 17044012
references: Neuromuscul Disord. 2010 Jul;20(7):471-5
references: 20554202
references: N Engl J Med. 1993 Dec 30;329(27):1993-2000
references: 8247075
references: Arch Dermatol. 2008 Oct;144(10):1341-9
references: 18936398
references: Brain. 2009 Jun;132(Pt 6):1536-44
references: 19454532